Patents by Inventor Myung Eun Jung
Myung Eun Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210161111Abstract: The present invention relates to a factor VIII or factor IX gene knockout rabbit, a method for preparing the same and a use thereof and, more particularly, to a transgenic rabbit whose factor VIII or factor IX gene has been knocked out through the CRISPR/Cas9 system, a method for preparing the same and a use thereof. According to the present invention, in the transgenic rabbit, whose factor VIII and/or factor IX gene has been knocked out, the functions of factor VIII and/or factor IX, which are proteins that perform critical functions for the development of hemophilia, are inhibited, such that the transgenic rabbit is useful for the development of hemophilia treatments.Type: ApplicationFiled: September 20, 2018Publication date: June 3, 2021Inventors: So Ra KIM, Myung Eun JUNG, Min Jung KIM, Seung Hyun JO, Sung Ho HWANG, Hee Chun KWAK, Su Min LEE, Hyun Ja NAM
-
Publication number: 20200093899Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.Type: ApplicationFiled: November 27, 2019Publication date: March 26, 2020Applicants: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Jin-Kyung LEE, Han-Yeul BYUN, Myung-Eun JUNG, Kyu-Hyun LEE
-
Patent number: 10561713Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.Type: GrantFiled: July 4, 2016Date of Patent: February 18, 2020Assignees: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Jin-Kyung Lee, Han-Yeul Byun, Myung-Eun Jung, Kyu-Hyun Lee
-
Publication number: 20180303914Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.Type: ApplicationFiled: July 4, 2016Publication date: October 25, 2018Applicants: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Jin-Kyung LEE, Han-Yeul BYUN, Myung-Eun JUNG, Kyu-Hyun LEE
-
Patent number: 9701681Abstract: The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases.Type: GrantFiled: December 14, 2015Date of Patent: July 11, 2017Assignees: CMG PHARMACEUTICAL CO., LTD., HANDOK INC.Inventors: Moonsoo Kim, Chaewoon Lee, Gilnam Lee, Cheol Hwan Yoon, Jeongbeob Seo, Je Hak Kim, MinWoo Lee, Hankyul Jeong, Hyang Choi, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Hye Kyoung Kim, Jae Il Lee, Misoon Kim, Soongyu Choi
-
Patent number: 9371303Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.Type: GrantFiled: January 9, 2015Date of Patent: June 21, 2016Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang-Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
-
Publication number: 20160168156Abstract: The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases.Type: ApplicationFiled: December 14, 2015Publication date: June 16, 2016Inventors: Moonsoo Kim, Chaewoon Lee, Gilnam Lee, Cheolhwan Yoon, Jeongbeob Seo, Jay Hak Kim, Minwoo Lee, Hankyul Jeong, Hyang Choi, Myung Eun Jung, Ki Nam Lee, Hyun Jung Kim, Hye Kyoung Kim, Jae Il Lee, MinWoo Lee, Misoon Kim, Soongyu Choi
-
Patent number: 9340521Abstract: The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.Type: GrantFiled: March 18, 2013Date of Patent: May 17, 2016Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Jae Eun Kim, Kwang-Seop Song, Suk Ho Lee, Kisoo Park, Hee Jeong Seo, Min Ju Kim, Eun-Jung Park, So Ok Park, Younggyu Kong, Hyunku Kang, Ickhwan Son, Myung Eun Jung, Man-Young Cha, Hyun Jung Kim, Jun Sung Lee, Mi-Soon Kim, Min Woo Lee, Kinam Lee
-
Publication number: 20150152075Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.Type: ApplicationFiled: January 9, 2015Publication date: June 4, 2015Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Kwang-Seop SONG, Suk Ho LEE, Min Ju KIM, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, So Ok PARK, Hyunku KANG, Myung Eun JUNG, Kinam LEE, Hyun Jung KIM, Jun Sung LEE, Min Woo LEE, Mi-Soon KIM, Dong Ho HONG, Misuk KANG
-
Patent number: 9034921Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.Type: GrantFiled: June 1, 2012Date of Patent: May 19, 2015Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
-
Publication number: 20140274918Abstract: The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.Type: ApplicationFiled: March 18, 2013Publication date: September 18, 2014Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Jae Eun KIM, Kwang-Seop SONG, Suk Ho LEE, Kisoo PARK, Hee Jeong SEO, Min Ju KIM, Eun-Jung PARK, So Ok PARK, Younggyu KONG, Hyunku KANG, Ickhawn SON, Myung Eun JUNG, Man-Young CHA, Hyun Jung KIM, Jun Sung LEE, Mi-Soon KIM, Min Woo LEE, Kinam LEE
-
Patent number: 8835436Abstract: A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.Type: GrantFiled: July 9, 2010Date of Patent: September 16, 2014Assignee: Green Cross CorporationInventors: Jinhwa Lee, Hee Jeong Seo, Suk Youn Kang, Eun-Jung Park, Min Ju Kim, Suk Ho Lee, Jong Yup Kim, Jeongmin Kim, Myung Eun Jung, Hyun Jung Kim, Mi-soon Kim, Ho Kyun Han, Kwang Woo Ahn, Min Woo Lee, Ki-Nam Lee, Ae Nim Pae, Woo-Kyu Park
-
Patent number: 8785453Abstract: A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.Type: GrantFiled: November 5, 2010Date of Patent: July 22, 2014Assignee: Green Cross CorporationInventors: Jinhwa Lee, Eun-Jung Park, Suk Youn Kang, Younggyu Kong, Junwon Lee, Hyun Jung Kim, Myung Eun Jung, Ki-Nam Lee, Jeongmin Kim, Ae Nim Pae, Woo-Kyu Park
-
Publication number: 20140088079Abstract: The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.Type: ApplicationFiled: June 1, 2012Publication date: March 27, 2014Applicant: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon KIM, Dong Ho Hong, Misuk Kang
-
Patent number: 8541380Abstract: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.Type: GrantFiled: June 18, 2010Date of Patent: September 24, 2013Assignee: Green Cross CorporationInventors: Jinhwa Lee, Suk Ho Lee, Hee Jeong Seo, Min Ju Kim, Suk Youn Kang, Jeongmin Kim, Sung-Han Lee, Myung Eun Jung, Eun Jung Son, Kwang-Seop Song, Mi-Soon Kim
-
Patent number: 8309584Abstract: A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.Type: GrantFiled: September 25, 2008Date of Patent: November 13, 2012Assignee: Green Cross CorporationInventors: Jinhwa Lee, Hee Jeong Seo, Min-Ah Kim, Jeongmin Kim, Sung-Han Lee, Myung Eun Jung, Mi-Soon Kim
-
Publication number: 20120232090Abstract: A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.Type: ApplicationFiled: November 5, 2010Publication date: September 13, 2012Applicant: GREEN CROSS CORPORATIONInventors: Jinhwa Lee, Eun-Jung Park, Suk Youn Kang, Younggyu Kong, Junwon Lee, Hyun Jung Kim, Myung Eun Jung, Ki-Nam Lee, Jeongmin Kim, Ae Nim Pae, Woo-Kyu Park
-
Patent number: 8178551Abstract: The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease.Type: GrantFiled: March 7, 2008Date of Patent: May 15, 2012Assignee: Green Cross CorporationInventors: Jinhwa Lee, Jeongmin Kim, Myung Eun Jung, Jong Yup Kim, Kwang-Seop Song, Eun Jung Son, Suk Ho Lee, Ho Kyun Han, Min Ju Kim, MinWoo Lee
-
Publication number: 20120115881Abstract: A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.Type: ApplicationFiled: July 9, 2010Publication date: May 10, 2012Applicant: GREEN CROSS CORPORATIONInventors: Jinhwa Lee, Hee Jeong Seo, Suk Youn Kang, Eun-Jung Park, Min Ju Kim, Suk Ho Lee, Jong yup Kim, Jeongmin Kim, Myung Eun Jung, Hyun Jung Kim, Mi-soon Kim, Ho kyun Han, Kwang Woo Ahn, Min Woo Lee, Ki-Nam Lee, Ae Nim Pae, Woo-Kyu Park
-
Publication number: 20120101051Abstract: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.Type: ApplicationFiled: June 18, 2010Publication date: April 26, 2012Applicant: GREEN CROSS CORPORATIONInventors: Jinhwa Lee, Suk Ho Lee, Hee Jeong Seo, Min Ju Kim, Suk Youn Kang, Jeongmin Kim, Sung-Han Lee, Myung Eun Jung, Eun Jung Son, Kwang-Seop Song, Mi-Soon Kim